Clinical value of soluble urokinase type plasminogen activator receptors in chronic kidney disease. Issue 38 (September 2019)

• Record Type: Journal Article
• Authors: Ahmed, Reem M.; Khalil, Mona A.; Ibrahim, Amal H.; Eid, Hanaa M.; Abdelbasset, Walid Kamal; Soliman, Gaber S.
• Other Names: Parekh. Parag section editor.
• Is Part Of: Medicine. Volume 98:Issue 38(2019)
• Publication Date: 2019-09
• Subjects: chronic kidney disease -- focal segmental glomerulosclerosis -- soluble urokinase type plasminogen activator receptors; Medicine -- Periodicals; Medicine -- Periodicals; Médecine -- Périodiques; Geneeskunde; Medicine; Periodicals; Periodicals; 610.5
• DOI: 10.1097/MD.0000000000017146
• Languages: English
• ISSNs: 0025-7974

Abstract

Abstract : Abstract: Chronic kidney disease (CKD) will progress to end stage without treatment, the decline off renal function may not linear. A sensitive marker such as soluble urokinase-type plasminogen activator receptors (suPARs) may allow potential intervention and treatment in earlier stages of CKD. Objectives: This study was designed to measure plasma (suPAR) in patients with CKD with different stages and to find its correlation with the disease severity. Methods: This study was conducted on 114 subjects, 84 were patients with different stages and different causes of CKD, and 30 healthy subjects as controls. Blood urea, serum creatinine, serum high-sensitive C-reactive protein, estimated glomerular filtration rate, and 24 hours proteinuria were measured, renal biopsy was done for all patients, and plasma (suPAR) was measured using enzyme-linked immunosorbent assay. Results: suPAR plasma levels were significantly higher in patients with CKD (7.9 ± 3.82 ng/mL) than controls (1.76 ± 0.77 ng/mL, P < .001). suPAR correlated with the disease severity. In stage 1 to 2 group, it was 3.7 ± 1.5 ng/mL, in stage 3 to 4, it was 10.10 ± 1.22 ng/mL, and in stage 5 group, it was 12.34 ± 0.88 ng/mL; the difference between the 3 groups was highly significant ( P < .001). A cutoff point 2.5 ng/mL of suPAR was found between controls and stage 1 group. According to the cause of CKD, although patients with obstructive cause and those with focal glomerulosclerosis had the higher levels 9.11 ± 3.32 ng/mL and 8.73 ± 3.19 ng/mL, respectively, but there was no significant difference between patients with CKD according to the cause of the CKD. Conclusion: Plasma (suPAR) increased in patients with CKD and correlated with disease severity.